Fatal outcome of sleep apnoea in PWS during the initial phase of growth hormone treatment. A case report.
The case of a boy with Prader-Willi syndrome (PWS) who suffered from respiratory problems since birth and suddenly died at the age of 6.5 years, 4 months after initiation of GH therapy, is presented. This case indicates the possibility of fatal courses in infants and children with PWS as a consequence of respiratory problems and raises the question as to a causal connection between the initiation of GH therapy and the sudden death of this child.
Eiholzer
Urs
U
Foundation Growth Puberty Adolescence, Zürich, Switzerland. urs.eiholzer@childgrowth.org
Nordmann
Yves
Y
L'Allemand
Dagmar
D
D002675:Child, Preschool; D003645:Death, Sudden / Q000209:etiology*; D017809:Fatal Outcome; D013006:Growth Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D011218:Prader-Willi Syndrome / Q000150:complications* / Q000188:drug therapy*; D012140:Respiratory Tract Diseases / Q000209:etiology / Q000503:physiopathology; D012891:Sleep Apnea Syndromes / Q000209:etiology*
D013006:Growth Hormone